TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)
Stopped Company operational decision. Decision to stop study is not due to safety or efficacy concerns.
Conditions
- Advanced Cancer
- Advanced Solid Tumor
- Cancer
- Oncology
Interventions
- DRUG: TT-816
- DRUG: A PD-1 inhibitor
Sponsor
Teon Therapeutics, Inc.
Collaborators